UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CAR T-cell therapy: Balance of efficacy and safety

Molecular biology (New York), 2017-03, Vol.51 (2), p.237-250

2017

Volltextzugriff (PDF)

Engineering Chimeric Antigen Receptors

Actanaturae, 2017-01, Vol.9 (1), p.6-14

2017

Volltextzugriff (PDF)

Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling

Cytotherapy (Oxford, England), 2017-05, Vol.19 (5), p.S9-S9

2017

Volltextzugriff (PDF)

Immunotherapy: MECHANISMS REGULATING THE RESISTANCE OF NORMAL T-CELLS TO CD5 CAR-MEDIATED CYTOTOXICITY

Cytotherapy (Oxford, England), 2022-05, Vol.24 (5), p.S39

2022

Volltextzugriff (PDF)

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

BLOOD, 2021-11, Vol.138 (Supplement 1), p.4800-4800

2021

Volltextzugriff (PDF)

Immunotherapy: SIGNALING DOMAINS, 41BB AND CD28, MEDIATE DISTINCT MOLECULAR DYNAMICS AT THE IMMUNE SYNAPSE THAT INFLUENCE CAR T CELL KILLING BEHAVIOR

Cytotherapy (Oxford, England), 2022-05, Vol.24 (5), p.S116-S117

2022

Volltextzugriff (PDF)

Long term follow up of subsequent malignancies in patients treated with genetically modified immune effectors

Cytotherapy (Oxford, England), 2021-05, Vol.23 (5), p.S151-S151

2021

Volltextzugriff (PDF)

A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy

CANCER RESEARCH, 2022, Vol.82 (12)

2022

Volltextzugriff (PDF)

6 - Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling

Cytotherapy (Oxford, England), 2017-05, Vol.19 (5), p.S9-S9

2017

Volltextzugriff (PDF)

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

Cell reports (Cambridge), 2017-10, Vol.21 (1), p.17-26

2017

Volltextzugriff (PDF)

CD7 CAR: sword and shield

Blood, 2022-07, Vol.140 (4), p.293-294

2022

Volltextzugriff (PDF)

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies

Blood, 2017-07, Vol.130 (3), p.285-296

2017

Volltextzugriff (PDF)

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells

The Journal of immunology (1950), 2017-07, Vol.199 (1), p.348-362

2017

Volltextzugriff (PDF)

Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1

Molecular therapy, 2017-09, Vol.25 (9), p.2202-2213

2017

Volltextzugriff (PDF)

Engineering T cells to prevent graft-versus-host disease and leukemia relapse following allogeneic stem cell transplantation

The Journal of immunology (1950), 2022-05, Vol.208 (1_Supplement), p.175-175.22

2022

Volltextzugriff (PDF)

CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia

Molecular therapy, 2019-01, Vol.27 (1), p.272-280

2019

Volltextzugriff (PDF)

Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies

Blood, 2022-12, Vol.140 (25), p.2684-2696

2022

Volltextzugriff (PDF)

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood, 2024-03, Vol.143 (13), p.1231-1241

2024

Volltextzugriff (PDF)

Effect of the killing style of individual CAR T cells on the clinicopathological behavior of therapeutic products in the clinic

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2548-2548

2023

Volltextzugriff (PDF)

Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia

Blood, 2024-04, Vol.143 (17), p.1726-1737

2024

Volltextzugriff (PDF)

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.4547-4548

2022

Volltextzugriff (PDF)

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Blood, 2023-03, Vol.141 (10), p.1194-1208

2023

Volltextzugriff (PDF)

CAR T Cells Targeted with a High Affinity Scfv Against the HCMV Glycoprotein Gb As Adoptive T Cell Therapy after Hematopoietic Stem Cell Transplantation

Blood, 2016-12, Vol.128 (22), p.5721-5721

2016

Volltextzugriff (PDF)

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application

Journal for immunotherapy of cancer, 2015-02, Vol.3 (1), p.5, Article 5

2015

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(32)
Tagungsberichte
(1)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(13)
Animals
(7)
Hematology
(7)
Mice
(6)
Lymphocytes T
(5)
Receptors, Antigen, T-Cell - Genetics
(5)
Chimeric Antigen Receptor
(4)
Chimeric Antigen Receptors
(4)
Gene Expression
(4)
Receptors, Antigen, T-Cell - Immunology
(4)
T Cells
(4)
T-Lymphocytes - Immunology
(4)
Antigens
(3)
Cancer
(3)
Cytotoxicity
(3)
Cytotoxicity, Immunologic
(3)
Hematologic Neoplasms - Therapy
(3)
Immunology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(11)
Cytotherapy
(5)
Biology Of Blood And Marrow Transplantation
(2)
Molecular Therapy
(2)
The Journal Of Immunology
(2)
Transplantation And Cellular Therapy
(2)
Acta Naturae
(1)
Actanaturae
(1)
Cancer Research
(1)
Cell Reports
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CAR T-cell therapy: Balance of efficacy and safety

Engineering Chimeric Antigen Receptors

Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling

Immunotherapy: MECHANISMS REGULATING THE RESISTANCE OF NORMAL T-CELLS TO CD5 CAR-MEDIATED CYTOTOXICITY

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

Immunotherapy: SIGNALING DOMAINS, 41BB AND CD28, MEDIATE DISTINCT MOLECULAR DYNAMICS AT THE IMMUNE SYNAPSE THAT INFLUENCE CAR T CELL KILLING BEHAVIOR

Long term follow up of subsequent malignancies in patients treated with genetically modified immune effectors

A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy

6 - Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

CD7 CAR: sword and shield

CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells

Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1

Engineering T cells to prevent graft-versus-host disease and leukemia relapse following allogeneic stem cell transplantation

CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia

Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Effect of the killing style of individual CAR T cells on the clinicopathological behavior of therapeutic products in the clinic

Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

CAR T Cells Targeted with a High Affinity Scfv Against the HCMV Glycoprotein Gb As Adoptive T Cell Therapy after Hematopoietic Stem Cell Transplantation

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application

Suchergebnisse filtern